ACRO Biomedical Co., Ltd. (TPEX:6748)

ACRO Biomedical Statistics

Total Valuation

ACRO Biomedical has a market cap or net worth of TWD 4.00 billion. The enterprise value is 3.56 billion.

Market Cap	4.00B
Enterprise Value	3.56B

Important Dates

The next estimated earnings date is Friday, November 14, 2025.

Earnings Date	Nov 14, 2025
Ex-Dividend Date	n/a

Share Statistics

ACRO Biomedical has 61.22 million shares outstanding. The number of shares has increased by 6.10% in one year.

Current Share Class	61.22M
Shares Outstanding	61.22M
Shares Change (YoY)	+6.10%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	17.24%
Owned by Institutions (%)	n/a
Float	43.60M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	109.52
PB Ratio	6.88
P/TBV Ratio	6.95
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-44.57
EV / Sales	97.46
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-51.34

Financial Position

The company has a current ratio of 28.89, with a Debt / Equity ratio of 0.02.

Current Ratio	28.89
Quick Ratio	27.49
Debt / Equity	0.02
Debt / EBITDA	n/a
Debt / FCF	-0.19
Interest Coverage	-314.17

Financial Efficiency

Return on equity (ROE) is -12.86% and return on invested capital (ROIC) is -7.89%.

Return on Equity (ROE)	-12.86%
Return on Assets (ROA)	-7.76%
Return on Invested Capital (ROIC)	-7.89%
Return on Capital Employed (ROCE)	-13.61%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.06
Inventory Turnover	1.82

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +174.95% in the last 52 weeks. The beta is 0.65, so ACRO Biomedical's price volatility has been lower than the market average.

Beta (5Y)	0.65
52-Week Price Change	+174.95%
50-Day Moving Average	76.55
200-Day Moving Average	45.08
Relative Strength Index (RSI)	34.02
Average Volume (20 Days)	419,689

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, ACRO Biomedical had revenue of TWD 36.50 million and -79.82 million in losses. Loss per share was -1.30.

Revenue	36.50M
Gross Profit	17.54M
Operating Income	-80.43M
Pretax Income	-79.82M
Net Income	-79.82M
EBITDA	-71.02M
EBIT	-80.43M
Loss Per Share	-1.30

Balance Sheet

The company has 453.27 million in cash and 13.20 million in debt, giving a net cash position of 440.07 million or 7.19 per share.

Cash & Cash Equivalents	453.27M
Total Debt	13.20M
Net Cash	440.07M
Net Cash Per Share	7.19
Equity (Book Value)	581.44M
Book Value Per Share	9.50
Working Capital	464.73M

Cash Flow

In the last 12 months, operating cash flow was -49.89 million and capital expenditures -19.40 million, giving a free cash flow of -69.30 million.

Operating Cash Flow	-49.89M
Capital Expenditures	-19.40M
Free Cash Flow	-69.30M
FCF Per Share	-1.13

Margins

Gross margin is 48.06%, with operating and profit margins of -220.34% and -218.69%.

Gross Margin	48.06%
Operating Margin	-220.34%
Pretax Margin	-218.69%
Profit Margin	-218.69%
EBITDA Margin	-194.58%
EBIT Margin	-220.34%
FCF Margin	n/a

Dividends & Yields

ACRO Biomedical does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-6.10%
Shareholder Yield	n/a
Earnings Yield	-2.00%
FCF Yield	-1.73%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

ACRO Biomedical has an Altman Z-Score of 40.75 and a Piotroski F-Score of 1.

Altman Z-Score	40.75
Piotroski F-Score	1